Role of viral infections in the induction of adverse drug reactions

Drug Safety

Volumn 16, Issue 1, 1997, Pages 1-8

  Levy, Micha ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMPICILLIN; CAFFEINE; COTRIMOXAZOLE; DIPYRONE; FLUCONAZOLE; INFLUENZA VACCINE; METHOTREXATE; NITRITE; PARACETAMOL; SULFAMETHOXAZOLE; SULFONAMIDE; THEOPHYLLINE;

ADVERSE DRUG REACTION; AGRANULOCYTOSIS; ASTHMA; DRUG HYPERSENSITIVITY; DRUG METABOLISM; EPSTEIN BARR VIRUS; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTIOUS MONONUCLEOSIS; INFLUENZA; KAPOSI SARCOMA; LIVER TOXICITY; LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PRURITUS; REVIEW; REYE SYNDROME; VIRUS INFECTION;

EID: 0031026096     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199716010-00001     Document Type: Review

References (77)

1. Evans ES. The clinical illness promotion factor - a third ingredient. Yale J Biol Med 1982; 55: 193-9
2. Levy M. The combined effect of viruses and drugs in drug-induced diseases. Med Hypotheses 1984; 14: 293-6
3. Haverkos HW, Amsel Z, Drotman DP. Adverse virus-drug interactions. Rev Infect Dis 1991; 13: 697-704
4. Pullen H, Wright N, Murdoch JM. Hypersensitivity reactions to antibacterial drugs in infectious mononucleosis. Lancet 1967; II: 1176-8
5. McKenzie H, Parratt D, White RG. IgM and IgG antibody levels Io ampicillin in patients with infectious mononucleosis. Clin Exp Immunol 1976; 26: 214-21
6. Williams RC, Kenyon AJ, Huntley CC. Immunoglobulins, viruses and speculation on their interrelationship in certain human and animal disease states. Blood 1968; 31: 522-35
7. Nazareth I, Mortimer P, McKendrick GD. Ampicillin sensitivity in infectious mononucleosis-temporary or permanent? Scand J Infect Dis 1972; 4: 229-31
8. Report of a collaborative study group: a prospective study of ampicillin rash. BMJ 1973; 1: 7-9
9. Gregg I. Ampicillin rash and influenza [letter]. BMJ 1973; 1: 295
10. Reye RDK, Morgan G, Baral J. Encephalopathy and fatty degeneration of the viscera: a disease entity of childhood. Lancet 1963; II: 749-52
11. Starko KM, Ray CG, Dominguez LB, et al. Reye's syndrome and salicylate use. Pediatrics 1980; 66: 859-64
12. Waldman RJ, Hall WN, McGee H, et al. Aspirin as a risk factor in Reye's syndrome. JAMA 1982; 274: 3089-94
13. Maheady DC. Reye's syndrome: review and update. J Pediatr Health Care 1989; 3: 246-50
14. Hurwitz ES. The changing epidemiology of Reye's syndrome in the United States: further evidence of a public health success. JAMA 1988; 260: 3178-80
15. Peters LJ, Wiener GJ, Gilliam J, et al. Reye's Syndrome in adults, a case report and review of the literature. Arch Intern Med 1986; 146: 2401-3
16. Gordin FM, Simons GL, Wofsy CB, et al. Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1984; 100: 495-9
17. Medina I, Mills J, Leoung G, et al. Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: a controlled trial of trimethoprim -sulfamethoxazole versus trimethoprim-dapsone. N Engl J Med 1990; 323: 776-82
18. Jaffe HS, Abrams DI, Amman AJ, et al. Complications of cotrimoxazole of AIDS-associated Pneumocystis carinii pneumonia in homosexual men. Lancet 1983; II: 1109-11
19. Van der Ven AJAM, Koopmans PP, Vree TB, et al. Adverse reactions to co-trimethoxazole in HIV infection. Lancet 1991; 338: 431-3
20. Cribb AE, Spielberg SP. Sulfamethoxazole is metabolized to the hydroxylamine in humans. Clin Pharmacol Ther 1992; 51: 522-6
21. Carr A, Swandson C, Penny R, et al. Clinical and laboratory markers of hypersensitivity to trimethoprim/sulfamethoxazole in patients with pneumocystis carinii pneumonia and AIDS. J Infect Dis 1993; 167: 180-5
22. Ackerman Z, Levy M. Hypersensitivity reactions to drugs in acquired immunodeficiency syndrome. Postgrad Med J 1987; 63: 55-6
23. Coopman MA, Johnson RA, Platt R, et al. Cutaneous disease and drug reactions in HIV infection. N Engl J Med 1993; 328: 1670-4
24. Havercos HW, Pinsky PF, Drotman DP, et al. Disease manifestation among homosexual men with acquired immunodeficiency syndrome: a possible role of nitrites in Kaposi's sarcoma. Sex Transm Dis 1985; 12: 203-8
25. Archibald CP, Schechter MT, Le TN, et al. Evidence of a sexually transmitted cofactor for AIDS-related Kaposi's sarcoma in a cohort of homosexual men. Epidemiology 1992; 3: 203-9
26. Haverkos HW, Kopstein AN, Wilson H, et al. Nitrite inhalants: history, epidemiology and possible links to AIDS. Environ Health Perspect 1994; 102: 858-61
27. Mirvish SS, Williamson J, Babcook D, et al. Mutagenicity of iso-butyl nitrite vapor in the Ames test and some relevant chemical properties, including the reaction of iso-butyl nitrite with phosphate. Environ Mol Mutagen 1993; 21: 247-52
28. Macdonald MG, McGrath PP, McMartin DN. Potentiation of the toxic effects of acetaminophen in mice by concurrent infection with influenza B virus: a possible mechanism for human Reye's syndrome. Pediatr Res 1984; 18: 181-7
29. Renton KW, Dickson G. The prevention of acetaminophen-induced hepatotoxicity by the interferon inducer poly (r 1. r C). Toxicol Appl Pharmacol 1984; 72: 40-5
30. Rosenberg DM, Meyer AA, Manning IH, et al. Acetaminophen and hepatic dysfunction in infectious mononucleosis. South Med J 1977; 70: 660-1
31. Ackerman Z, Flugelman MY, Wax Y, et al. Hepatitis during measles in young adults: possible role of antipyretic drugs. Hepatology 1989; 10: 203-6
32. Kaufman DW, Kelly JP, Levy M, et al. The drug etiology of agranulocytosis and aplastic anemia. New York: Oxford University Press, 1991
33. Levy M, Kelly JP, Kaufman DW, et al. Risk of agranulocytosis and aplastic anemia in relation to history of intectious mononuclcosis: a report from the International Agranulocytosis and Aplastic Anemia Study. Ann Hematol 1993; 67: 187-90
34. Purtilo DT. Epstein-Barr virus: the spectrum of its manifestations in human beings. South Med J 1987; 80: 943-7
35. Szczeklik A. Aspirin-induced asthma as a viral disease. Clin Allergy 1988; 18: 15-20
36. Kamel OW, Van de Rijn M, Weiss LM, et al. Reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med 1993; 328: 1317-21
37. Bass NM, Williams RL. Guide to drug dosage in hepatic disease. Clin Pharmacokinet 1988; 15: 396-420
38. McLean AJ, Morgan DJ. Clinical pharmacokinetics in patients with liver disease. Clin Pharmacokinet 1991; 21: 42-69
39. Joanne C, Paintaud G, Bresson-Hadni S, et al. Is debrisoquine hydroxylation modified during acute viral hepatitis? Fundam Clin Pharmacol 1994; 8: 76-9
40. Lee BL, Wong D, Benowitz NL, et al. Altered patterns of drug metabolism in patients with acquired immunodeficiency syndrome. Clin Pharmacol Ther 1993; 53: 529-35
41. Dolomenie C, Grant DM, Mathelier-Fusade P, et al. N-acetylation genotype and risk of severe reactions to sulphonamides in AIDS patients. Br J Clin Pharmacol 1994; 38: 581-2
42. Kaufman GR, Wenk M, Taeschner W, et al. N-acetyltransferase 2 polymorphism in patients infected with human immunodeficiency virus. Clin Pharmacol Ther 1996; 60: 62-7
43. Singh G, Renton KW. Interferon-mediated depression of cytochrome P-450 dependent drug biotransformation. Mol Pharmacol 1981; 20: 681-4
44. Renton KW, Knickle LC. Regulation of hepatic cytochrome P-450 during infectious diseases. Can J Physiol Pharmacol 1990; 68: 777-81
45. Ghezzi P, Bianchi M, Gianera L, et al. Role of reactive oxygen intermediates in the interferon-mediated depression of hepatic drug metabolism and protective effect of N-acetylcysteine in mice. Cancer Res 1985; 45: 3444-7
46. Proulx M, du Souich P. Inflammation-induced decrease in hepatic cytochrome P450 in conscious rabbits is accompanied by an increase in hepatic oxidative stress. Res Commun Mol Pathol Pharmacol 1995; 87: 221-36
47. Rieder MJ, Shear NH, Kanee A, et al. Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions. Clin Pharmacol Ther 1991; 49: 13-7
48. Carr A, Gross AS, Hoskins JM, et al. Acetylation phenotype and cutaneous hypersensitivity to trimethoprim sulphamethoxazole in HIV-infected patients. AIDS 1994; 8: 333-7
49. Shear NH, Spielberg SP, Grant DM, et al. Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Ann Intern Med 1986; 105: 179-87
50. Buhl R, Jaffe HA, Holroyd KJ, et al. Systemic glutathione deficiency in symptom-free HIV-sero-positive individuals. Lancet 1989: II: 1294-8
51. Van der Ven AJAM, Vree TB, Van Ewijk-Beneken Kolmer EWJ, et al. Urinary recovery and kinetics of sulphamethoxazole and its metabolites in HIV seropositive patients and healthy volunteers after a single oral dose of sulphamethoxazole. Br J Clin Pharmacol 1995; 39: 621-5
52. Rieder MJ, Uetrecht J, Shear NH, et al. Diagnosis of sulfonamide hypersensitivity reactions by in vitro 'rechallenge' with hydroxylamine metabolites. Ann Intern Med 1989; 110: 286-9
53. Carr A, Tindall B, Penny R, et al. In vitro cytotoxicity as a marker of cytotoxicity to sulphamethoxazole in patients with human immunodeficiency virus (HIV) infection. Clin Exp Immunol 1993; 94: 21-5
54. DeMuria D, Forrest A, Rich J, et al. Pharmacokinetics and bioavailability of fluconazole in patients with AIDS. Antimicrob Agents Chemother 1993; 37: 2187-92
55. Yeates RAM, Rahnke Y, Pfau SA, et al. The pharmacokinetics of fluconazole after a single intravenous dose in AIDS patients. Br J Clin Pharmacol 1994; 38: 77-9
56. Tett S, Moore S, Ray J. Pharmacokinetics and bioavailability of fluconazole in two groups of males with human immunodeficiency virus (HIV) infection compared with those in a group of males without HIV infection. Antimicrob Agents Chemother 1995; 39: 1835-41
57. Gatti G, Flaherty J, Bubp J, et al. Comparative study of bioavailability and pharmacokinetics of clindamycin in healthy volunteers and patients with AIDS. Antimicrob Agents Chemother 1993; 37: 1137-43
58. Levy M, Zylber-Katz E, Rosenkranz B. Clinical pharmacokinetics of dipyrone and its metabolites. Clin Pharmacokinet 1995; 28: 216-34
59. Levy M, Leibowitz Y, Ilan Y, et al. Dipyrone metabolites kinetics in carriers of hepatitis B virus with normal liver function tests: preliminary results [abstract]. Therapie 1995; Suppl.: 482
60. Svensson CK, Knowlton PW. Effect of the immunomodulator tilorone on the in vivo acetylation of procainamide in the rat. Pharm Res 1989; 6: 477-80
61. Kramer P, McClain C. Depression of aminopyrine metabolism by influenza vaccination. N Engl J Med 1981; 305: 1262-4
62. Chang CK, Lauer BA, Bell TD, et al. Altered theophylline pharmacokinetics during acute respiratory viral illness. Lancet 1978; I: 1132-3
63. Kraemer MJ, Furukawa CT, Coup J, et al. Altered theophylline clearance during an influenza B outbreak. Paediatrics 1982; 69: 476-80
64. Renton KW. Theophylline pharmacokinetics in respiratory viral illness. Lancet 1978; II: 160-1
65. Renton KW, Gray JD, Hall RI. Decreased elimination of theophylline after influenza vaccination. Can Med Assoc J 1980; 125: 288-90
66. Walker S, Schreiber L, Middelkamp C. Serum theophylline levels after influenza vaccination. Can Med Assoc J 1981; 125: 243-4
67. Meredith CG, Christian CD, Johnson RF, et al. Effects of influenza virus vaccine on hepatic drug metabolism. Clin Pharmacol Ther 1985; 37: 396-401
68. Goldstein RS, Cheung OT, Seguin R, et al. Decreased elimination of theophylline after influenza vaccination. Can Med Assoc J 1982; 126: 470
69. San Joaquin VH, Reyes S, Marks MI. Influenza vaccination in asthmatic children on maintenance theophylline therapy. Clin Pediatr 1982; 21: 724-6
70. Fischer RG, Booth BJ, Mitchell DQ, et al. Influence of trivalent influenza vaccine on serum theophylline levels. Can Med Assoc J 1982; 126: 1312-3
71. Grabowski N, May JJ, Prett DS. No effect of split virus influenza vaccination on theophylline pharmacokinetics. Am Rev Respir Dis 1985; 131: 934-8
72. Kortabarria R, Duran JA, Abadin JA, et al. Influenza vaccination and plasma concentrations of theophylline in patients with asthma and COPD. Clin Drug Invest 1995; 9: 161-5
73. Hannan SE, May JJ, Pratt DS, et al. The effect of whole virus influenza vaccination on theophylline pharmacokinetics. Am Rev Respir Dis 1988; 137: 903-6
74. Kramer P, McClain CJ. Depression of aminopyrine metabolism by influenza vaccination. N Engl J Med 1981; 305: 1262-4
75. Kramer P, Tsuru M, Cook CE, et al. Effects of influenza vaccine on warfarin anticoagulation. Clin Pharmacol Ther 1984; 35: 416-8
76. Lipsky BA, Pecoraro NJ, Roben NJ, et al. The effect of the influenza vaccination (IV) on warfarin anticoagulation. Ann Intern Med 1984; 100: 835-7
77. Rieder MI, Bird IA, Dekaban GA. Kinetics of increased sensitivity to sulfonamide reactive metabolites in HIV-infected cells [abstract]. Clin Pharmacol Ther 1995; 57: 135